Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US
This study uses data from the US nationwide electronic health record–based Epic Cosmos Dataset to examine prescriptions for semaglutide and tirzepatide, focusing on differences across race, ethnicity, social vulnerability, and urbanicity and assess the need for strategies to promote equitable access to these therapies.
Authors
- Ania M. Jastreboff (ORCID: https://orcid.org/0000-0003-1446-0991)
- Joseph S. Ross (ORCID: https://orcid.org/0000-0002-9218-3320)
- Chungsoo Kim (ORCID: https://orcid.org/0000-0003-1802-1777)
- Yuan Lu (ORCID: https://orcid.org/0000-0001-5264-2169)
- Harlan M. Krumholz (ORCID: https://orcid.org/0000-0003-2046-127X)
- Daniella Meeker (ORCID: https://orcid.org/0000-0002-1034-7628)
- Harry Freedman
Institutions
- Yale New Haven Hospital (US)
- Yale University (US)
- Epic Systems (United States) (US)
Publication Details
- Journal
- JAMA
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1001/jama.2025.4735
- Citations
- 20
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 25.90